These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 20977679

  • 1. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):163-70. PubMed ID: 20977679
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
    Huang F, Scholl P, Huang DB, MacGregor TR, Vinisko R, Castles MA, Berger F, Robinson P.
    J Clin Pharmacol; 2011 Jul; 51(7):1061-70. PubMed ID: 20705951
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L, ARTEN investigators.
    Antivir Ther; 2011 Jul; 16(3):339-48. PubMed ID: 21555816
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.
    Clin Infect Dis; 2009 Nov 15; 49(10):1591-601. PubMed ID: 19842973
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
    Ramanathan S, Shen G, Cheng A, Kearney BP.
    J Acquir Immune Defic Syndr; 2007 Jul 01; 45(3):274-9. PubMed ID: 17414929
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers.
    Yerino GA, Halabe EK, Zini E, Feleder EC.
    Arzneimittelforschung; 2011 Jul 01; 61(1):55-60. PubMed ID: 21355446
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
    Hoetelmans RM, Mariën K, De Pauw M, Hill A, Peeters M, Sekar V, De Doncker P, Woodfall B, Lefebvre E.
    Br J Clin Pharmacol; 2007 Nov 01; 64(5):655-61. PubMed ID: 17610528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.